OABI
OmniAb, Inc.
Biotechnology · Healthcare · United States
5.11
close · 2026-10-30
value
74
cheaper than peers74
quality
90
stronger fundamentals90
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | 0.1% | 84 |
| cash flow yield, 3 years ago | -2.8% | 72 |
| earnings yield, 3 years ago | -5.1% | 71 |
| cash flow yield, 1 year ago | -5.6% | 66 |
| cash flow yield, latest year | -5.0% | 63 |
| earnings yield, 2 years ago | -10.0% | 63 |
| price to book | 2.85× | 58 |
| earnings yield, 1 year ago | -11.9% | 56 |
| earnings yield, latest year | -11.2% | 53 |
| price to sales | 19.32× | 37 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 244.2% | 86 |
| return on equity | -17.0% | 74 |
| debt to equity | 7.3% | 68 |
| operating margin | -49.5% | 61 |
4 of 4 measures available
Facts
| market cap | $743M |
| free cash flow | -$285,000 |
| employees | 89 |
| first trade | 2021-09-30 |
| next earnings | 2026-10-30 |
| fundamentals updated | 2026-10-30 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.57 | -0.61 | -0.51 | -0.26 |
| free cash flow | -$37.0M | -$41.5M | $703,000 | -$20.8M |
| net income | -$64.8M | -$62.0M | -$50.6M | -$22.3M |
| revenue | $18.7M | $26.4M | $34.2M | $59.1M |